ADVB (Advanced Biomed) 3-Year EBITDA Growth Rate: -93.70% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $8.90
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed 3-Year EBITDA Growth Rate?

Advanced Biomed ADVB +76.94% 12 3-Year EBITDA Growth Rate is -93.70% as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 167 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 97.01% on this metric.

Advanced Biomed's EBITDA per Share for the three months ended in Mar. 2026 was $-0.37.

During the past 3 years, the average EBITDA Per Share Growth Rate was -93.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Advanced Biomed was -6.40% per year. The lowest was -93.70% per year. And the median was -50.05% per year.

Advanced Biomed  (NAS:ADVB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Advanced Biomed 3-Year EBITDA Growth Rate Related Terms

ADVB vs MBAI, XWEL, NDRA: 3-Year EBITDA Growth Rate Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Biomed 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's 3-Year EBITDA Growth Rate falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -93.70% mean?
Advanced Biomed (ADVB) has a 3-Year EBITDA Growth Rate of -93.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #162 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 97%.
Is Advanced Biomed's 3-Year EBITDA Growth Rate too high?
Advanced Biomed's current 3-Year EBITDA Growth Rate is -93.70%. Based on the distribution chart, Advanced Biomed ranks #162 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's 3-Year EBITDA Growth Rate compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #162 out of 167 companies for 3-Year EBITDA Growth Rate. This places Advanced Biomed in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current 3-Year EBITDA Growth Rate is -93.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current 3-Year EBITDA Growth Rate of -93.70%. The current 3-Year EBITDA Growth Rate is -93.70%. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current 3-Year EBITDA Growth Rate is -93.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.90
Price